hit counter

New Antidepressant GLYX-13 (Clinical Trials): Partial NMDA Receptor Agonist

A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an antidepressant augmentation strategy, meaning it is used as an add-on to already approved treatments. However, most evidence would suggest that it works extremely well as a standalone treatment option. …

Read more

Suboxone (Buprenorphine) For Treatment-Resistant Depression: Partial Mu-Opioid Agonist

Suboxone (Buprenorphine) is a medication that is used by people withdrawing from narcotics (opioids). It helps alleviate withdrawal symptoms and most people end up able to experience a smooth withdrawal while on this particular drug. In people that have either extreme or treatment-resistant depression, many have turned to trying a variety of drugs besides that …

Read more